NCT01327859View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

PHASE3CompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Parkinson's DiseaseDementia
Interventions
DRUG

Prior Donepezil 5mg

Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.

DRUG

Prior Donzepezil 10mg

Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.

DRUG

Prior Placebo

Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.

Trial Locations (1)

BA2 5RP

Bath

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01327859 - Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia | Biotech Hunter | Biotech Hunter